Lineage Cell Therapeutics, Inc. - FORM 10-K - EX-21.1 - EXHIBIT 21.1 - March 11, 2015

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Lineage Cell Therapeutics, Inc.Financial_Report.xls
EX-32 - EXHIBIT 32.1 - Lineage Cell Therapeutics, Inc.ex32.htm
EX-31 - EXHIBIT 31 - Lineage Cell Therapeutics, Inc.ex31.htm
EX-23.1 - EXHIBIT 23.1 - Lineage Cell Therapeutics, Inc.ex23_1.htm
EX-23.2 - EXHIBIT 23.2 - Lineage Cell Therapeutics, Inc.ex23_2.htm
EX-10.65 - EXHIBIT 10.65 - Lineage Cell Therapeutics, Inc.ex10_65.htm
EX-10.62 - EXHIBIT 10.62 - Lineage Cell Therapeutics, Inc.ex10_62.htm
EX-10.61 - EXHIBIT 10.61 - Lineage Cell Therapeutics, Inc.ex10_61.htm
EX-10.64 - EXHIBIT 10.64 - Lineage Cell Therapeutics, Inc.ex10_64.htm
EX-10.63 - EXHIBIT 10.63 - Lineage Cell Therapeutics, Inc.ex10_63.htm
10-K - BIOTIME, INC 10-K 12-31-2014 - Lineage Cell Therapeutics, Inc.form10k.htm
Exhibit 21.1

List of Subsidiaries

Subsidiary
BioTime Ownership
Country
Asterias Biotherapeutics, Inc.
67.5%
USA
BioTime Asia, Limited
81%
Hong Kong
Cell Cure Neurosciences Ltd.
62.5%(1)
Israel
ES Cell International Pte Ltd
100%
Singapore
LifeMap Sciences, Inc.
74.52%
USA
LifeMap Sciences, Ltd.
(2)
Israel
LifeMap Solutions, Inc.
(2)
USA
OncoCyte Corporation
75.3%
USA
OrthoCyte Corporation
100%(3)
USA
ReCyte Therapeutics, Inc.
94.8%
USA

(1) Includes shares owned by BioTime, Asterias Biotherapeutics, Inc. and ES Cell International Pte Ltd.
(2) LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.
(3) Includes shares owned by BioTime and Asterias Biotherapeutics, Inc.
 
 

Lineage Cell Therapeutics, Inc. Reports